An announcement from NLS Pharmaceutics ( (NLSP) ) is now available.
On February 27, 2025, NLS Pharmaceutics announced new preclinical data for AEX-2, a non-sulfonamide dual orexin receptor agonist, highlighting its potential for treating narcolepsy and related neurological disorders. The findings suggest AEX-2 offers a safer and more targeted alternative to existing therapies, with significant advancements in wakefulness enhancement, REM sleep preservation, and cataplexy reduction. The company, in collaboration with Aexon Labs, is also exploring the broader therapeutic applications of AEX-2 and AEX-41 in neurodegenerative and metabolic disorders, with plans to advance these compounds into clinical trials by 2026.
More about NLS Pharmaceutics
NLS Pharmaceutics is a global biopharmaceutical company focused on developing next-generation therapies for sleep disorders, neurodegenerative diseases, and metabolic dysfunctions. Through a strategic licensing agreement with Aexon Labs, NLS is advancing a portfolio of non-sulfonamide dual orexin receptor agonists (DOXA), including AEX-2 and AEX-41, designed to restore sleep-wake balance, reduce neuroinflammation, and address metabolic dysregulation.
YTD Price Performance: -17.66%
Average Trading Volume: 2,974,551
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.44M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.